natgillin/translations-raw huggingface dataset:
I dette studie blandede størstedelen af patienterne (79%) deres kortvarigt virkende insulin med NPH insulin lige før injektionen, og 58% af patienterne brugte orale antidiabetika ved randomiseringen og fik besked på fortsat at bruge disse i uændret dosis.
In this study, the majority of patients (79%) mixed their short acting insulin with NPH insulin immediately prior to injection and 58% of subjects used oral hypoglycemic agents at randomization and were instructed to continue to use them at the same dose.
I dette studie blev 1.002 patienter randomiseret i et 2x2 faktor design til en af følgende fire arme:
In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:
I dette studie blev 1.987 patienter randomiseret til behandling med capecitabin (1.250 mg/m2 to gange dagligt i 2 uger, efterfulgt af en uges pause, givet som 3-ugers serier i 24 uger) eller til behandling med 5-FU og leucovorin (Mayo Clinic-regime:
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as
I dette studie blev 150 patienter med NYHA funktionsklasse III-IV hjerteinsufficiens (venstre ventrikels uddrivningsfraktion ≤ 35 %) behandlet med 3 infusioner infliximab 5 mg/kg, 10 mg/kg eller placebo i løbet af 6 uger.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤35%) were treated with 3 infusions of infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
I dette studie blev 150 patienter med NYHA funktionsklasse III-IV hjerteinsufficiens (venstre ventrikels uddrivningsfraktion ≤ 35 %) behandlet med 3 infusioner Remicade 5 mg/kg, 10 mg/kg eller placebo i løbet af 6 uger.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of Remicade 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
I dette studie blev 160 patienter randomisered til behandling med capecitabin (1.000 mg/m2 to gange dagligt i 2 uger efterfulgt af 7 dages pause) og cisplatin (80 mg/m2 som en 2- timers infusion hver 3. uge).
In this trial, 160 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period) and cisplatin (80 mg/m2 as a 2-hour infusion every 3 weeks).
I dette studie blev 160 patienter randomiseret til behandling med capecitabin (1.000 mg/m2 to gange dagligt i 2 uger efterfulgt af 7 dages pause) og cisplatin (80 mg/m2 som en 2- timers infusion hver 3. uge).
In this trial, 160 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period) and cisplatin (80 mg/m2 as a 2-hour infusion every 3 weeks).
I dette studie blev 255 patienter randomiseret til behandling med docetaxel (75 mg/m² som intravenøs infusion over 1 time hver 3. uge) og capecitabin (1.250 mg/m² 2 gange dagligt i 2 uger efterfulgt af 1 uges pause).
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m² as a 1 hour intravenous infusion every weeks) and capecitabine (1250 mg/m² twice daily for 2 weeks followed by 1-week rest period).
I dette studie blev 312 patienter randomiseret (2:1) til enten 50 mg sunitinib eller placebo, oralt 1 gang dagligt med doseringsskema 4/2 indtil sygdomsprogression, eller til de udgik af studiet af anden årsag (207 patienter fik sunitinib, og 105 patienter fik placebo).
In this study, 312 patients were randomized (2:1) to receive either 50 mg sunitinib or placebo, orally once daily on Schedule 4/2 until disease progression or withdrawal from the study for another reason (207 patients received sunitinib and 105 patients received placebo).
I dette studie blev 358 patienter med inoperabelt, lokalt fremskreden SCCHN og WHO funktionsstatus 0 eller 1, randomiseret i en af to behandlingsarme.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomized to one of two treatment arms.
I dette studie blev 358 patienter med inoperabelt, lokalt fremskreden SCCHN og WHO funktionsstatus 0 eller 1, randomiseret i en af to behandlingsarme.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms.
I dette studie blev 501 patienter med lokalt fremskredent SCCHN og en WHO-funktionsstatus på 0 eller 1, randomiseret i en af to arme.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
I dette studie blev der anvendt en modifikation af det terapeutiske Zevalin regimen med en lavere [90Y]-Zevalin aktivitet i forhold til legemsvægt (11 MBq/kg).
In this study, a modification of the Zevalin therapeutic regimen with a lower [90Y]-Zevalin activity per body weight (11 MBq/kg) was used.
I dette studie blev der anvendt to metoder til at klassificere nyrefunktionen: kreatininclearance i urinen målt over 24 timer, og den kreatininclearance, der blev estimeret ud fra Cockcroft-Gault-ligningen.
In this study, two methods were used to classify renal function: the urinary creatinine clearance measured over 24 hours and the creatinine clearance estimated by Cockcroft-Gault formula.
I dette studie blev der ikke observeret nogen vaccinerelaterede alvorlige uønskede hændelser.
In this trial no vaccine related SAEs were observed.
I dette studie blev kun kemoterapi-naive forsøgspersoner, som ikke fik anden kemoterapi efter endt operation, behandlet med lave kumulative doser af epirubicin, dvs. op til 300 mg/m2.
In this study, only chemotherapy-naive subjects, not receiving additional chemotherapy after surgery, were treated with low cumulative dose of epirubicin, i.e. up to 300 mg/m2.
I dette studie blev tillæg af 300 mg aliskiren sammenlignet med tillæg af placebo til standardbehandling, som inkluderede enten en angiotensin-konverteringshæmmer eller en angiotensin- receptorblokker.
In this study, aliskiren 300 mg was compared to placebo when added to standard of care which included either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.
I dette studie blev varig beskyttelse i op til cirka 8 år påvist statistisk.
In this study, a durable protection was statistically demonstrated to approximately 8 years.
I dette studie deltog 543 randomiserede patienter, som gennemgik en transplantation; 184 med belatacept MI, 175 med belatacept og 184 med ciclosporin.
In this study, 543 patients were enrolled, randomised, and transplanted; 184 to belatacept MI, 175 to belatacept LI, and 184 to ciclosporin.
I dette studie fik patienterne en daglig dosis oral opløsning på 20 mg/kg, 25 mg/kg, 40 mg/kg eller 50 mg/kg baseret på en titreringsplan i forhold til deres alder.
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule.
I dette studie forekom hyponatriæmi i ranolazin-gruppen sjældent.
In this study the frequency of hyponatraemia in the ranolazine group was rare.
I dette studie havde 29,1 % af patienterne indledningsvist responderede utilstrækkeligt (primære ikke-respondenter), 69,4 % responderede, men respons ophørte efterfølgende (sekundære ikke-respondenter) og 36,4 % af patienterne var intolerante over for anti-TNF-alfa-terapi.
In this study, 29.1% of the patients had an inadequate initial response (primary non-responders), 69.4% responded but lost response (secondary non-responders), and 36.4% were intolerant to anti- TNFα therapies.
I dette studie havde 29,1 % af patienterne indledningsvist responderet utilstrækkeligt (primære ikke-respondenter), 69,4 % responderede, men respons ophørte efterfølgende (sekundære ikke-respondenter), og 36,4 % af patienterne var intolerante over for anti-TNF-alfa-terapi.
In this study, 29.1% of the patients had an inadequate initial response (primary non-responders), 69.4% responded but lost response (secondary non-responders), and 36.4% were intolerant to anti- TNFα therapies.
I dette studie havde patienter behandlet med alirocumab, som udviklede ADA, en lavere forekomst af reaktioner på injektionsstedet sammenlignet med patienter, som ikke udviklede ADA (8,6% vs 16,2%).
In this study, patients treated with alirocumab who developed ADA had a lower incidence of injection site reactions compared with patients who did not develop ADA (8.6% vs 16.2%).
I dette studie med deltagelse af mandlige patienter med LUTS/BOO var den justerede gennemsnitlige ændring fra baseline til behandlingsafslutning (SE) i restmængden efter tømning (ml) 0,55 (10,702), 17,89 (10,190), 30,77 (10,598) for placebo-, mirabegron 50 mg- og mirabegron 100 mg- behandlingsgrupperne.
In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (mL) was 0.55 (10.702), 17.89 (10.190), 30.77 (10.598) for the placebo, mirabegron 50 mg and mirabegron 100 mg treatment groups.
I dette studie så man bivirkninger som kvalme, svimmelhed, hypotension og synkope ved samtidig administration af trazodon og ritonavir.
Adverse events of nausea, dizziness, hypotension and syncope have been observed following co- administration of trazodone and ritonavir in this study.
I dette studie udviste AT-armen højere forekomst af svær neutropeni (90% mod 68,6%), febril neutropeni (33,3% mod 10%), infektion (8% mod 2,4%), diarré (7,5% mod 1,4%), asteni (8,5% mod 2,4%) og smerter (2,8% mod 0%) end AC-armen.
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
I dette studie undersøgte man ikke-splenektomerede patienter med ITP og trombocyttal < 50 x 109/l.
This study evaluated non-splenectomised patients with ITP and platelet counts < 50 x 109/l.
I dette studie var 5 patienter yngre end 2 år og 13 patienter var i alderen 2 til under 6 år.
In this study, 5 patients were <2 years and 13 between 2 to
I dette studie var de fleste psoriasisartrit patienter behandlet med Enbrel i stand til at rejse en effektivt B-celle immunrespons mod pneumokok polysakkarid vaccine, men aggregattitrene var moderat lavere, og få patienter havde dobbelt stigning i titrene i sammenligning med patienter, som ikke fik Enbrel.
In this study, most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients had two-fold rises in titres compared to patients not receiving Enbrel.
I dette studie var de fleste psoriasisartrit patienter behandlet med Enbrel i stand til at rejse en effektivt B-celle immunrespons mod pneumokok polysakkarid vaccine, men aggregrattitrene var moderat lavere, og få patienter havde dobbelt stigning i titrene i sammenligning med patienter, som ikke fik Enbrel.
In this study most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and few patients had two-fold rises in titers compared to patients not receiving Enbrel.
I dette studie var de fleste psoriasisartrit patienter behandlet med Enbrel i stand til at rejse en effektivt B-celle immunrespons mod pneumokok-polysakkarid-vaccine, men aggregattitrene var moderat lavere, og få patienter havde dobbelt stigning i titrene i sammenligning med patienter, som ikke fik Enbrel.
In this study, most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients had two-fold rises in titres compared to patients not receiving Enbrel.
I dette studie var de observerede bivirkninger i overensstemmelse med den kendte bivirkningsprofil for hver af behandlingerne, inklusiv vedvarende vægtøgning ved rosiglitazon.
In this study, the adverse events observed were consistent with the known adverse event profile for each of the treatments, including continuing
I dette studie var de observerede bivirkninger i overensstemmelse med den kendte bivirkningsprofil for hver af behandlingerne, inklusive vedvarende vægtøgning ved rosiglitazon.
consistent with the known adverse event profile for each of the treatments, including continuing weight gain with rosiglitazone.
I dette studie var de observerede bivirkninger i overensstemmelse med den kendte bivirkningsprofil for hver af behandlingerne, inklusive vedvarende vægtøgning ved rosiglitazon.
In this study, the adverse events observed were consistent with the known adverse event profile for each of the treatments, including continuing
I dette studie var den gennemsnitlige clearance hos børn
In this trial, the mean clearance in children was
I dette studie var den objektive responsrate 36,5% (95% CI: 24,7%-49,6%) og mediantiden til progression (TTP) var 37,7 uger (95% CI: 24,0-46,4 uger).
In this study the objective response rate was 36.5% (95% CI: 24.7% - 49.6%) and the median time to progression (TTP) was 37.7 weeks (95% CI: 24.0 - 46.4 weeks).
I dette studie var der 1 tilfælde af dødelig intrakranial blødning blandt 16 patienter, der fik lenvatinib og havde CNS- metastaser ved baseline.
In this trial, there was 1 case of fatal intracranial haemorrhage among 16 patients who received lenvatinib and had CNS metastases at baseline.
I dette studie var der fra dag 9 til og med dag 21 op til 64 % fald i dalkoncentrationen for etinyløstradiol og et fald på op til 60
During days 9 through 21 in this study, there was as much as a 64 % decrease in ethinyl estradiol trough concentrations and as much as a 60 % decrease in norethindrone trough concentrations.
I dette studie var frekvensen for tilbagefald over en 12-måneders periode 20 % for lurasidon og 16 % for risperidon.
In that study the rate of relapse over a 12-month period was 20% for lurasidone and 16% for risperidone.
I dette studie var hyppigheden (95% CI) per 100 forsøgspersonårs opfølgning 0,40 (0,01; 2,20) for lymfomer, 0,79 (0,10; 2,86) for non-melanom hudkræft og 1,99 (0,64; 4,63) for andre maligne sygdomme.
In this study, the incidence (95% CI) per 100 subject-years of follow-up in golimumab-treated subjects was 0.40 (0.01, 2.20) for lymphoma, 0.79 (0.10, 2.86) for non-melanoma skin cancers, and 1.99 (0.64, 4.63) for other malignancies.
I dette studie var median TTP 34,0 uger (95% CI = 22,0-46,0 uger).
In this study, the median TTP was 34.0 weeks (95% CI = 22.0 – 46.0 weeks).
I dette studie var middelvolumen for distribution ved steady state 47 ml/kg, gennemsnitlig opholdstid (MRT) var 15,5 dage, og gennemsnitlig clearance var 0,13 ml/kg.
In this trial the mean volume of distribution at steady state was 47 ml/kg, mean residence time was 15.5 days and mean clearance was
I dette studie var naloxegol i doser på 12,5 mg og 25 mg generelt sikre og veltolererede sammenlignet med placebo ved behandling af patienter med opioidinduceret obstipation og ikke- cancerrelaterede smerter.
In this study, naloxegol at doses of 12.5 mg and 25 mg was generally safe and well tolerated as compared with placebo in the treatment of OIC patients with non-cancer-related pain.
I dette studie var ORR 35,8% (95% CI: 26,8%-47,5%.
In this study the ORR was 35.8% (95% CI: 26.8% – 47.5 %).
I dette studie var patienterne 65-75 år; 41 % (183/447) af patienterne var 70 år eller derover.
In this study the age range of patients was 65-75 years, with 41% (183/447) of patients 70 years old or older.
I dette studie var procentdelen af eosinofile celler i sputum i reslizumab- gruppen reduceret med 82 % ved behandlingens afslutning fra en gennemsnitsværdi ved baseline på 17,4 % (standardafvigelse 15,9 %).
In this study, the percentage of sputum eosinophils was reduced from a mean baseline value of 17.4% (standard deviation: 15.9%) by 82% at end of therapy in the reslizumab group.
I dette studie var steady-state- plasmakoncentrationen ved en dosis på 300 mg hos rygere 1,22 µg/ml (n=17).
Steady-state trough plasma concentrations at a 300 mg dose in current smokers in this study was 1.22 µg/mL (n=17).
I dette studie var tiden til 20% af total AUC og AUC (0-2 timer), som udtryk for den tidlige blodglucosesænkende effekt, henholdsvis 114 minutter og 427 mg/kg for insulin glulisin, 121 minutter og 354 mg/kg for lispro, 150 minutter og 197 mg/kg for regular human insulin (se figur 2).
In this study, the time to 20% of total AUC and the AUC (0-2h) representing the early glucose lowering activity were respectively of 114 minutes and 427 mg/kg for insulin glulisine, 121 minutes and 354 mg/kg for lispro, 150 minutes and 197 mg/kg for regular human insulin (see figure 2).
I dette studie var tiden til 20% af total AUC og AUC (0-2 timer), som udtryk for den tidlige glucosesænkende effekt, henholdsvis 114 minutter og 427 mg/kg for insulin glulisin, 121 minutter og 354 mg/kg1 for lispro, 150 minutter og 197 mg/kg for regular human insulin (se figur 2).
In this study, the time to 20 % of total AUC and the AUC (0-2h) representing the early glucose lowering activity were respectively of 114 minutes and 427 mg/kg for insulin glulisine, 121 minutes and 354 mg/kg for lispro, 150 minutes and 197 mg/kg for regular human insulin (see figure 2).
I dette studie var tiden til 20% af total AUC og AUC (0-2 timer), som udtryk for den tidlige glucosesænkende effekt, henholdsvis 114 minutter og 427 mg/kg for insulin glulisin, 121 minutter og 354 mg/kg1 for lispro, 150 minutter og 197 mg/kg for regular human insulin (se figur 2).
In this study, the time to 20% of total AUC and the AUC (0-2h) representing the early glucose lowering activity were respectively of 114 minutes and 427 mg/kg for insulin glulisine, 121 minutes and 354 mg/kg for lispro, 150 minutes and 197 mg/kg for regular human insulin (see figure 2).
I dette studie viste AT-armen en hyppigere forekomst af alvorlig neutropeni (90 % versus 68,6 %), febril neutropeni (33,3 % versus 10 %), infektion (8 % versus 2,4 %), diarré (7,5 % versus 1,4 %), asteni (8,5 % versus 2,4 %) og smerter ((2,4 % versus 0 %) end AC-armen.
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
I dette studie viste AT-armen en hyppigere forekomst af alvorlig neutropeni (90 % versus 68,6 %), febril neutropeni (33,3 % versus 10 %), infektion (8 % versus 2,4 %), diarré (7,5 % versus 1,4 %), asteni (8,5 % versus 2,4 %) og smerter (2,4 % versus 0 %) end AC-armen.
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
I dette studie viste Sprimeo HCT i doser fra 150 mg/12,5 mg til 300 mg/25 mg dosisafhængige blodtryksreduktioner (systolisk/diastolisk) fra henholdsvis 17,6/11,9 mmHg til 21,2/14,3 mmHg, sammenlignet med 7,5/6,9 mmHg for placebo.
In this study, Sprimeo HCT in doses from 150 mg/12.5 mg to 300 mg/25 mg produced dose-dependent blood pressure reductions (systolic/diastolic) from 17.6/11.9 mmHg to
I dette studiet var start- og vedligeholdelsesdosis af leflunomid baseret på 3 vægtkategorier: < 20 kg, 20 - 40 kg og >40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20 - 40 kg, and > 40 kg.
I dette studiet var start- og vedligeholdelsesdosis af leflunomid baseret på 3 vægtkategorier: <20 kg, 20-40 kg og >40kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20-40 kg, and > 40 kg.
I dette studiet var start- og vedligeholdelsesdosis af leflunomid baseret på 3 vægtkategorier: <20 kg, 20-40 kg og >40kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg.
I dette studium havde 87 % af patienterne sygdom, som var IHC 3+, og 95 % af de inkluderede patienter havde sygdom, som var IHC3+ og/eller patienterne var FISH-positive.
In this study, 87% of patients had disease that was IHC 3+, and 95% of patients entered had disease that was IHC 3+ and/or FISH positive.
I dette studium havde langsomme acetylatorer flere bivirkninger end hurtige acetylatorer.
In this study, slow acetylators experienced more adverse reactions than the fast acetylators.
I dette tidsrum lå koncentrationerne af skatol og androstenon under de tærskelværdier, der forbindes med risikoen for ornelugt.
During this period, concentrations of skatole and androstenone were below the threshold levels associated with the risk of boar taint.
I dette tidsrum skal bruse- og karbad undgås.
During this period, showering and bathing should be avoided.
I dette tilfæde, kan du komme indholdet af hver hård kapsel i én teske med æblemos, og derefter tage det straks.
If so, you may sprinkle the content of each hard capsule in one teaspoon of apple sauce and take it immediately.
I dette tilfælde er der klargjort 12 enheder.
In this example, 12 units are loaded.
I dette tilfælde er udløbsdatoen udgangen af denne 6 måneders periode eller den udløbsdato, der er tryk på hætteglassets etiket, hvis denne dato kommer først.
In this case, this medicine expires at the end of this 6 month period or the expiration date printed on the product vial, whichever is earlier.
I dette tilfælde hedder cellerne lymfoblaster. en type lymfom kaldet T-celle lymfoblastær lymfom.
In this case, its cells called lymphoblasts. a type of lymphoma, called T-cell lymphoblastic lymphoma.
I dette tilfælde holder vaccinens virkning i op til fem uger.
In this case, the effect of the vaccine lasts for up to 5 weeks.
I dette tilfælde kan du muligvis have en arvelig fejl i blodets størkning; hvis du skal opereres, eller hvis du sidder eller ligger ned i længere tid på grund af en skade eller sygdom, eller hvis du har benet i gips.
In this case you could have a hereditary blood clotting disorder; if you need to have an operation, or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast.
I dette tilfælde kan lægen tage regelmæssige blodprøver med særlig henblik på at måle kaliumniveauet i blodet, hvis nyrefunktionen er nedsat
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function
I dette tilfælde kan lægen tage regelmæssige blodprøver med særlig henblik på at måle kaliumniveauet i blodet, hvis nyrefunktionen er nedsat
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function,
I dette tilfælde kan lægen tage regelmæssige blodprøver med særlig henblik på at måle kaliumniveauet i blodet, hvis nyrefunktionen er nedsat hvis du skal opereres eller bedøves.
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function if you are going to have an operation (surgery) or be given anaesthetics
I dette tilfælde kan lægen tage regelmæssige blodprøver med særlig henblik på at måle kaliumniveauet i blodet, hvis nyrefunktionen er nedsat. hvis du skal opereres eller bedøves.
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function if you are going to have an operation (surgery) or be given anaesthetics
I dette tilfælde må infusionsvæsken ikke anvendes, men skal kasseres.
In this case, the solution must not be used and should be discarded.
I dette tilfælde ordinerer din læge også medicin, som hjælper dig med at undgå denne type lungebetændelse (PCP). hvis De nogensinde har haft eller ved at De kan have hepatitis B infektion.
In this case, your doctor will also prescribe medicine to help you prevent this type of pneumonia (PCP). if you have ever had or might now have a hepatitis B infection.